0001479681-24-000008.txt : 20240808 0001479681-24-000008.hdr.sgml : 20240808 20240808160323 ACCESSION NUMBER: 0001479681-24-000008 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 17 CONFORMED PERIOD OF REPORT: 20240808 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20240808 DATE AS OF CHANGE: 20240808 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Nutex Health, Inc. CENTRAL INDEX KEY: 0001479681 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-BUSINESS SERVICES, NEC [7389] ORGANIZATION NAME: 07 Trade & Services IRS NUMBER: 113363609 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-41346 FILM NUMBER: 241188085 BUSINESS ADDRESS: STREET 1: 6030 S. RICE AVE. STREET 2: SUITE C CITY: HOUSTON STATE: TX ZIP: 77081 BUSINESS PHONE: (713) 660-0557 MAIL ADDRESS: STREET 1: 6030 S. RICE AVE. STREET 2: SUITE C CITY: HOUSTON STATE: TX ZIP: 77081 FORMER COMPANY: FORMER CONFORMED NAME: Clinigence Holdings, Inc. DATE OF NAME CHANGE: 20191113 FORMER COMPANY: FORMER CONFORMED NAME: iGambit, Inc. DATE OF NAME CHANGE: 20091230 8-K 1 nutx-20240808x8k.htm 8-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): August 8, 2024

NUTEX HEALTH INC.

(Exact name of registrant as specified in its charter)


Delaware	001-41346	11-3363609
(State or Other Jurisdiction of Incorporation)	(Commission File Number)	(I.R.S. Employer Identification Number)

‎6030 S. Rice Ave, Suite C, Houston, Texas 77081

(Address of principal executive offices) (zip code)

‎(713) 660-0557‎

(Registrant’s telephone number, including area code)

N/A

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Precommencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Precommencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:


Title of each class	Trading Symbols(s)	Name of each exchange on which registered
Common Stock, $0.001 par value	NUTX	The NASDAQ Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02.‎ Results of Operations and Financial Condition

On August 8, 2024, Nutex Health Inc. (the “Company”) announced its financial and operating results for the quarter ending June 30, 2024. A copy of the Company’s press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

Item 9.01 Financial Statements and Exhibits

(d) Exhibits


Exhibit No.	Description of Exhibit
99.1	Press Release dated August 8, 2024
104	Cover Page Interactive Data File - the cover page interactive data file does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.

THE INFORMATION CONTAINED IN ITEM 2.02 OF THIS CURRENT REPORT, INCLUDING EXHIBIT 99.1 ATTACHED HERETO, SHALL NOT BE DEEMED “FILED” FOR THE PURPOSES OF SECTION 18 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED, NOR SHALL IT BE DEEMED INCORPORATED BY REFERENCE INTO ANY REGISTRATION STATEMENT OR OTHER FILING PURSUANT TO THE SECURITIES ACT OF 1933, AS AMENDED, EXCEPT AS OTHERWISE EXPRESSLY STATED IN SUCH FILING

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.



	Date: August 8, 2024
	Nutex Health Inc.

	By: /s/ Jon C. Bates
	Jon C. Bates
	Chief Financial Officer

EX-99.1 2 nutx-20240808xex99d1.htm EX-99.1

NUTEX HEALTH reports SECOND quarter and Six months ended June 30, 2024 financial results

●

Total revenue of $143.5 million for THE first half 2024 vs $115.3 Million FOR THE first half 2023, an increase of 25%

●

HOSPITAL DIVISION VISITS OF 81,276 FOR THE first half 2024 VS VISITS OF 65,244 FOR THE first half 2023, An increase of 25%

●

hospital division operating income of $33.3 million for THE first half 2024 VS $13.9 million FOR THE first half 2023, an increase of 140%

●

Net cash from operating activities of $16.3 million for THE FIRST HALF 2024

●

COMPANY CONTINUES ITS FOCUS ON INCREASING CASH FLOW

HOUSTON, TX − (PRNewswire) – AUGUST 8, 2024 – Nutex Health Inc. (“Nutex Health” or the “Company”) (NASDAQ: NUTX), a physician-led, integrated healthcare delivery system comprised of 21 state-of-the-art micro hospitals and hospital outpatient departments (HOPDs) in nine states and primary care-centric, risk-bearing physician networks, today announced second quarter 2024 financial results for the three and six months ended June 30, 2024.

Financial Highlights for the Three Months Ended June 30, 2024:

●

Total revenue of $76.1 million as compared to total revenue of $58.9 million for the three months ended June 30, 2023, an increase of 29%. Of this revenue growth, mature hospitals, which are hospitals opened prior to December 31, 2021, increased by 13.2% in 2024 compared to the same period in 2023.

●

Net loss attributable to Nutex Health Inc. of $0.4 million as compared to net loss attributable to Nutex Health Inc. of $3.5 million for the three months ended June 30, 2023. This includes non-cash impairment of assets of $3.5 million, non-cash impairment of goodwill of $3.2 million and $3.1 million non-cash gain on warrant liability.

●

EBITDA, attributable to Nutex Health Inc. of $8.5 million as compared to EBITDA, attributable to Nutex Health Inc. of $3.7 million for the three months ended June 30, 2023.

●

Adjusted EBITDA, attributable to Nutex Health Inc. of $12.0 million as compared to Adjusted EBITDA, attributable to Nutex Health Inc. of $4.0 million for the three months ended June 30, 2023, an increase of 200%.

●

Total visits from the Hospital Division were 41,208 for the second quarter 2024 as compared to 32,183 for the second quarter 2023, an increase of 9,025 or 28.0%. Of this visit growth, mature hospitals increased by 10.3% in 2024 compared to the same period in 2023.

Financial Highlights for the Six Months Ended June 30, 2024:

●

Total revenue of $143.5 million as compared to total revenue of $115.3 million for the six months ended June 30, 2023, an increase of approximately 25%. Of this revenue growth, mature hospitals, which are hospitals opened prior to December 31, 2021, increased by 10.0% in 2024 compared to 2023.

●

Net loss attributable to Nutex Health Inc. of $0.7 million as compared to net loss attributable to Nutex Health Inc. of $8.6 million for the six months ended June 30, 2023. This includes non-cash impairment of assets of $3.5 million, non-cash impairment of goodwill of $3.2 million and $5.7 million non-cash gain on warrant liability in the first six months of 2024.

●

EBITDA, attributable to Nutex Health Inc. of $15.6 million as compared to EBITDA, attributable to Nutex Health Inc. of $4.1 million for the six months ended June 30, 2023.

●

Adjusted EBITDA, attributable to Nutex Health Inc. of $16.6 million as compared to Adjusted EBITDA, attributable to Nutex Health Inc. of $6.4 million for the six months ended June 30, 2023, an increase of 159%.

●

Total visits from the Hospital Division were 81,276 for the six months ended June 30, 2024 as compared to 65,244 for the same period in 2023, an increase of 16,032 or 24.6%. Of this visit growth, mature hospitals increased by 9.7% in the six months ended June 30, 2024 compared to the same period in 2023.

●

Net cash from operating activities of $16.3 million. As of June 30, 2024, the Company had total assets of $422.4 million, including cash and cash equivalents of $40.8 million and long-term debt of $22.4 million.

Note: EBITDA and Adjusted EBITDA are non-GAAP financial metrics. A reconciliation of non-GAAP to GAAP measures is included below in this earnings release.

Page 1 of 8

“We are pleased to report 29% revenue growth, Adjusted EBITDA, attributable to Nutex Health Inc. of $12.0 million and a 150% increase in hospital division operating income to $22.8 million in the second quarter ended June 30, 2024, showing our continued focus on top line growth, increasing cash flow as well as improving profitability,” stated Jon Bates, Chief Financial Officer of Nutex Health.

“Nutex Health is executing extremely well, and we plan to continue to advance our strategic initiatives to drive sustainable growth. We delivered solid revenue growth while accelerating cash flow and strengthening our balance sheet in the first half of 2024. We are confident that we are taking the right steps to lay the foundation for long-term success and to increasing shareholder value,” stated Warren Hosseinion, M.D., President of Nutex Health.

“We had a solid Second Quarter with strong year over year growth. Volume continues to increase overall among our hospitals. Our average payment by insurers of patient claims increased, a trend we are optimistic will persist as we continue to work the NSA claims through the Independent Dispute Resolution process,” stated Tom Vo, M.D., MBA, Chairman and Chief Executive Officer of Nutex Health.

For more details on the Company’s Second Quarter 2024 financial results, please refer to our Quarterly Report on Form 10-Q filed with the U.S. Securities & Exchange Commission and accessible at www.sec.gov.

Page 2 of 8

NUTEX HEALTH INC.

CONDENSED CONSOLIDATED BALANCE SHEETS

(Unaudited)


	June 30, 2024		December 31, 2023
Assets
Current assets:
Cash and cash equivalents	$	40,807,975	$	22,002,056
Accounts receivable		60,658,832		58,624,301
Accounts receivable - related parties		4,577,189		4,152,068
Inventories		2,759,448		3,390,584
Prepaid expenses and other current assets		5,066,994		2,679,394
Total current assets		113,870,438		90,848,403
Property and equipment, net		78,881,900		81,387,649
Operating right-of-use assets		11,690,957		11,853,082
Finance right-of-use assets		187,096,271		176,146,329
Intangible assets, net		16,180,504		20,512,636
Goodwill, net		13,918,719		17,066,263
Other assets		764,462		431,135

Total assets	$	422,403,251	$	398,245,497

Liabilities and Equity
Current liabilities:
Accounts payable	$	16,742,370	$	18,899,196
Accounts payable - related parties		6,796,475		6,382,197
Lines of credit		2,909,296		3,371,676
Current portion of long-term debt		14,223,944		10,808,721
Operating lease liabilities, current portion		1,998,512		1,579,987
Finance lease liabilities, current portion		5,570,604		4,315,979
Accrued expenses and other current liabilities		23,417,191		12,955,296
Total current liabilities		71,658,392		58,313,052
Long-term debt, net		22,406,516		26,314,733
Warrant liability		2,000,714		-
Operating lease liabilities, net		14,690,566		15,479,639
Finance lease liabilities, net		226,820,535		213,886,213
Deferred tax liabilities		2,804,492		5,145,754
Total liabilities		340,381,215		319,139,391

Commitments and contingencies

Equity:
Common stock, $0.001 par value; 950,000,000 shares authorized; 4,987,268 and 4,511,199 shares issued and outstanding as of June 30, 2024 and December 31, 2023, respectively		4,988		4,511
Additional paid-in capital		472,529,641		470,521,218
Accumulated deficit		(409,800,662)		(409,072,539)
Nutex Health Inc. equity		62,733,967		61,453,190
Noncontrolling interests		19,288,069		17,652,916
Total equity		82,022,036		79,106,106

Total liabilities and equity	$	422,403,251	$	398,245,497

Page 3 of 8

NUTEX HEALTH INC.

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(Unaudited)


	Three Months Ended June 30,				Six Months Ended June 30,
	2024		2023		2024		2023
Revenue:
Hospital division	$	67,604,878	$	51,611,803	$	127,634,247	$	100,899,967
Population health management division		8,477,383		7,312,651		15,901,801		14,353,904
Total revenue		76,082,261		58,924,454		143,536,048		115,253,871

Operating costs and expenses:
Payroll and benefits		28,398,075		24,860,702		55,401,219		50,697,375
Contract services		9,505,222		9,747,873		20,824,676		18,937,204
Medical supplies		3,588,464		3,264,202		8,910,306		7,288,084
Depreciation and amortization		4,532,804		4,169,160		8,719,006		8,162,907
Other		7,496,465		7,235,594		16,962,432		15,673,655
Total operating costs and expenses		53,521,030		49,277,531		110,817,639		100,759,225

Gross profit		22,561,231		9,646,923		32,718,409		14,494,646

Corporate and other costs:
Facilities closing costs		-		-		-		217,266
Stock-based compensation expense		(61,241)		249,645		(12,074)		2,149,645
Impairment of assets		3,473,635		-		3,473,635		-
Impairment of goodwill		3,197,391		-		3,197,391		-
General and administrative expenses		10,652,390		9,759,816		19,310,800		16,935,360
Total corporate and other costs		17,262,175		10,009,461		25,969,752		19,302,271

Operating income (loss)		5,299,056		(362,538)		6,748,657		(4,807,625)

Interest expense, net		5,054,532		4,843,048		9,498,894		7,983,137
Gain on warrant liability		(3,060,096)		-		(5,660,843)		-
Other (income) expense		(599,502)		(123,528)		(840,694)		123,927
Income (loss) before taxes		3,904,122		(5,082,058)		3,751,300		(12,914,689)

Income tax expense (benefit)		893,892		(815,612)		1,283,557		(1,726,271)

Net income (loss)		3,010,230		(4,266,446)		2,467,743		(11,188,418)

Less: net income (loss) attributable to noncontrolling interests		3,374,278		(787,399)		3,195,866		(2,562,092)

Net loss attributable to Nutex Health Inc.	$	(364,048)	$	(3,479,047)	$	(728,123)	$	(8,626,326)

Loss per common share:
Basic	$	(0.07)	$	(0.79)	$	(0.15)	$	(1.98)
Diluted	$	(0.07)	$	(0.79)	$	(0.15)	$	(1.98)

Page 4 of 8

NUTEX HEALTH INC.

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(Unaudited)


	Six Months Ended June 30,
	2024		2023
Cash flows from operating activities:
Net income (loss)	$	2,467,743	$	(11,188,418)
Adjustments to reconcile net loss to net cash from operating activities:
Depreciation and amortization		8,719,006		8,162,907
Gain on warrant liability		(5,660,843)		-
Impairment of goodwill		3,197,391		-
Impairment of assets		3,473,635		-
Derecognition of goodwill		453,017		-
Stock-based compensation expense		(12,074)		2,149,645
Deferred tax benefit		(2,341,262)		(1,724,111)
Debt accretion expense		579,121		953,236
Loss on lease termination		-		58,211
Non-cash lease expense (income)		(208,423)		61,734
Changes in operating assets and liabilities, net of the effects of acquisitions:
Accounts receivable		(2,148,508)		6,921,239
Accounts receivable - related party		(425,121)		(797,058)
Inventories		631,136		1,082,509
Prepaid expenses and other current assets		(1,692,907)		(3,048,993)
Accounts payable		(1,617,151)		(7,189,929)
Accounts payable - related party		414,278		3,453
Accrued expenses and other current liabilities		10,481,831		5,619,907
Net cash from operating activities		16,310,869		1,064,332

Cash flows from investing activities:
Acquisitions of property and equipment		(1,291,492)		(7,446,902)
Cash related to sale of business		(711,306)		-
Cash related to deconsolidation of Real Estate Entities		-		(1,039,157)
Net cash from investing activities		(2,002,798)		(8,486,059)

Cash flows from financing activities:
Proceeds from lines of credit		132,167		1,949,919
Proceeds from notes payable		4,915,000		16,952,905
Repayments of lines of credit		(594,547)		(1,592,714)
Repayments of notes payable		(6,156,543)		(7,481,893)
Repayments of finance leases		(1,440,016)		(1,870,670)
Proceeds from common stock issuance, net issuance costs		9,202,500		-
Members' contributions		300,850		649,550
Members' distributions		(1,861,563)		(2,686,304)
Net cash from financing activities		4,497,848		5,920,793
Net change in cash and cash equivalents		18,805,919		(1,500,934)
Cash and cash equivalents - beginning of the period		22,002,056		34,255,264
Cash and cash equivalents - end of the period	$	40,807,975	$	32,754,330

Page 5 of 8

Non-GAAP Financial Measures (Unaudited)

EBITDA and Adjusted EBITDA. EBITDA and Adjusted EBITDA are used as a supplemental non-GAAP financial measure by management and external users of our financial statements, such as industry analysts, investors, lenders and rating agencies. We believe EBITDA and Adjusted EBITDA are useful because it allows us to more effectively evaluate our operating performance.

We define EBITDA as net income (loss) attributable to Nutex Health Inc. plus interest expense, income taxes, depreciation and amortization.

We define Adjusted EBITDA as net income (loss) attributable to Nutex Health Inc. plus net interest expense, income taxes, depreciation and amortization, further adjusted for an allocation to noncontrolling interests, (gain)/loss on warrant liability, stock-based compensation, certain defined items of expense, and any acquisition-related costs and impairments. A reconciliation of net income to EBITDA and Adjusted EBITDA is included below. EBITDA and Adjusted EBITDA are not intended to serve as an alternative to U.S. GAAP measures of performance and may not be comparable to similarly-titled measures presented by other companies.


	Three Months Ended June 30,				Six Months Ended June 30,
	2024		2023		2024		2023
Reconciliation of net loss attributable to Nutex Health Inc. to Adjusted EBITDA:
Net loss attributable to Nutex Health Inc.	$	(364,048)	$	(3,479,047)	$	(728,123)	$	(8,626,326)
Depreciation and amortization		4,532,804		4,169,160		8,719,006		8,162,907
Interest expense, net		5,054,532		4,843,048		9,498,894		7,983,137
Income tax expense (benefit)		893,892		(815,612)		1,283,557		(1,726,271)
Allocation to noncontrolling interests		(1,627,829)		(972,655)		(3,172,002)		(1,727,965)
EBITDA attributable to Nutex Health Inc.		8,489,351		3,744,894		15,601,332		4,065,482
Facilities closing costs		-		-		-		217,266
Gain on warrant liability		(3,060,096)		-		(5,660,843)		-
Impairment of assets		3,473,635				3,473,635
Impairment of goodwill		3,197,391		-		3,197,391		-
Stock-based compensation expense		(61,241)		249,645		(12,074)		2,149,645
Adjusted EBITDA attributable to Nutex Health Inc.	$	12,039,040	$	3,994,539	$	16,599,441	$	6,432,393

Page 6 of 8

About Nutex Health Inc.

Headquartered in Houston, Texas and founded in 2011, Nutex Health Inc. (NASDAQ: NUTX) is a healthcare management and operations company with two divisions: a Hospital Division and a Population Health Management Division.

The Hospital Division owns, develops and operates innovative health care models, including micro-hospitals, specialty hospitals, and hospital outpatient departments (HOPDs). This division owns and operates 21 facilities in nine states.

The Population Health Management division owns and operates provider networks such as Independent Physician Associations (IPAs). Through our Management Services Organization (MSO), we provide management, administrative and other support services to our affiliated hospitals and physician groups. Our cloud-based proprietary technology platform aggregates clinical and claims data across multiple settings, information systems and sources to create a holistic view of patients and providers, allowing us to deliver greater quality care more efficiently.

Page 7 of 8

Forward-Looking Statements

Certain statements and information included in this press release constitute "forward-looking statements" within the meaning of the Private Securities Litigation Act of 1995. When used in this press release, the words or phrases “will”, "will likely result," "expected to," "will continue," "anticipated," "estimate," "projected," "intend," “goal,” or similar expressions are intended to identify "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements are subject to certain risks, known and unknown, and uncertainties, many of which are beyond the control of the Company. Such uncertainties and risks include, but are not limited to, our ability to successfully execute our growth strategy, changes in laws or regulations, including the interim final and final rules implemented under the No Surprises Act , economic conditions, dependence on management, dilution to stockholders, lack of capital, the effects of rapid growth upon the Company and the ability of management to effectively respond to the growth and demand for products and services of the Company, newly developing technologies, the Company’s ability to compete, conflicts of interest in related party transactions, regulatory matters, protection of technology, lack of industry standards, the effects of competition and the ability of the Company to obtain future financing. An extensive list of factors that can affect future results are discussed in the Annual Report on Form 10-K for the year ended December 31, 2023 and in the Quarterly Report on Form 10-Q for the period ended March 31, 2024 under the heading “Risk Factors” in Part I, Item IA thereof, and other documents filed from time to time with the Securities and Exchange Commission. Such factors could materially adversely affect the Company's financial performance and could cause the Company's actual results for future periods to differ materially from any opinions or statements expressed within this press release.

FOR ADDITIONAL INFORMATION:

Nutex Health, Inc.

Jennifer Smith Rodriguez – Investor Relations

investors@nutexhealth.com

– Media Contact

jsmith@nutexhealth.com

Page 8 of 8

GRAPHIC 3 nutx-20240808xex99d1001.jpg GRAPHIC begin 644 nutx-20240808xex99d1001.jpg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end EX-101.SCH 4 nutx-20240808.xsd EX-101.SCH 00090 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink 99900 - Disclosure - Standard And Custom Axis Domain Defaults link:presentationLink link:calculationLink link:definitionLink EX-101.DEF 5 nutx-20240808_def.xml EX-101.DEF EX-101.LAB 6 nutx-20240808_lab.xml EX-101.LAB Entity Incorporation, State or Country Code Entity File Number Entity Tax Identification Number Entity Address, Address Line One Entity Address, Adress Line Two Entity Address, City or Town Entity Address State Or Province Entity Address, Postal Zip Code City Area Code Local Phone Number Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security Trading Symbol Security Exchange Name Entity Emerging Growth Company EX-101.PRE 7 nutx-20240808_pre.xml EX-101.PRE XML 9 R1.htm IDEA: XBRL DOCUMENT

Document and Entity Information	Aug. 08, 2024
Cover [Abstract]
Document Type	8-K
Document Period End Date	Aug. 08, 2024
Entity Registrant Name	NUTEX HEALTH INC.
Entity Incorporation, State or Country Code	DE
Entity File Number	001-41346
Entity Tax Identification Number	11-3363609
Entity Address, Address Line One	6030 S. Rice Ave
Entity Address, Adress Line Two	Suite C
Entity Address, City or Town	Houston
Entity Address State Or Province	TX
Entity Address, Postal Zip Code	77081
City Area Code	713
Local Phone Number	660-0557
Written Communications	false
Soliciting Material	false
Pre-commencement Tender Offer	false
Pre-commencement Issuer Tender Offer	false
Title of 12(b) Security	Common Stock, $0.001 par value
Trading Symbol	NUTX
Security Exchange Name	NASDAQ
Entity Emerging Growth Company	false
Entity Central Index Key	0001479681
Amendment Flag	false

XML 10 R2.htm IDEA: XBRL DOCUMENT

Document Information	Aug. 08, 2024
Document Information:
Document Type	8-K
Amendment	false
CIK	0001479681
Registrant Name	NUTEX HEALTH INC.
Period End Date	Aug. 08, 2024

EXCEL 11 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 12 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 13 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 15 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.2.u1 html 1 23 1 false 0 0 false 0 false false R1.htm 00090 - Document - Document and Entity Information Sheet http://nutexhealth.com/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false R2.htm 995200 - Document - Document Information Sheet http://xbrl.sec.gov/dei/role/document/DocumentInformation Document Information Cover 2 false false All Reports Book All Reports nutx-20240808.xsd nutx-20240808_def.xml nutx-20240808_lab.xml nutx-20240808_pre.xml nutx-20240808x8k.htm http://xbrl.sec.gov/dei/2024 true false JSON 17 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "nutx-20240808x8k.htm": { "nsprefix": "nutx", "nsuri": "http://nutexhealth.com/20240808", "dts": { "schema": { "local": [ "nutx-20240808.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/2014/extensible-enumerations.xsd", "http://www.xbrl.org/lrr/arcrole/esma-arcrole-2018-11-21.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd", "https://xbrl.sec.gov/country/2024/country-2024.xsd", "https://xbrl.sec.gov/country/2024/country-2024_def.xsd", "https://xbrl.sec.gov/dei/2024/dei-2024.xsd", "https://xbrl.sec.gov/rxp/2024/rxp-2024.xsd", "https://xbrl.sec.gov/snj/2024/snj-2024.xsd", "https://xbrl.sec.gov/snj/2024/snj-2024_def.xsd", "https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd" ] }, "definitionLink": { "local": [ "nutx-20240808_def.xml" ] }, "labelLink": { "local": [ "nutx-20240808_lab.xml" ] }, "presentationLink": { "local": [ "nutx-20240808_pre.xml" ] }, "inline": { "local": [ "nutx-20240808x8k.htm" ] } }, "keyStandard": 23, "keyCustom": 0, "axisStandard": 0, "axisCustom": 0, "memberStandard": 0, "memberCustom": 0, "hidden": { "total": 2, "http://xbrl.sec.gov/dei/2024": 2 }, "contextCount": 1, "entityCount": 1, "segmentCount": 0, "elementCount": 63, "unitCount": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2024": 23 }, "report": { "R1": { "role": "http://nutexhealth.com/role/DocumentDocumentAndEntityInformation", "longName": "00090 - Document - Document and Entity Information", "shortName": "Document and Entity Information", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "Duration_8_8_2024_To_8_8_2024_RaCnKdEilUiNpnHUVouBkg", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "p", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "nutx-20240808x8k.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_8_8_2024_To_8_8_2024_RaCnKdEilUiNpnHUVouBkg", "name": "dei:EntityIncorporationStateCountryCode", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "nutx-20240808x8k.htm", "unique": true } }, "R2": { "role": "http://xbrl.sec.gov/dei/role/document/DocumentInformation", "longName": "995200 - Document - Document Information", "shortName": "Document Information", "isDefault": "false", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "2", "firstAnchor": { "contextRef": "Duration_8_8_2024_To_8_8_2024_RaCnKdEilUiNpnHUVouBkg", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "p", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "nutx-20240808x8k.htm", "first": true }, "uniqueAnchor": null } }, "tag": { "rxp_A": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/rxp/2024", "localname": "A", "crdr": "debit", "presentation": [ "http://xbrl.sec.gov/rxp/role/Detail" ], "lang": { "en-us": { "role": { "label": "Amount", "terseLabel": "Amount" } } }, "auth_ref": [] }, "country_AllCountriesDomain": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/country/2024", "localname": "AllCountriesDomain", "presentation": [ "http://xbrl.sec.gov/rxp/role/ByGovernment" ], "lang": { "en-us": { "role": { "label": "All Countries [Domain]", "terseLabel": "All Countries" } } }, "auth_ref": [] }, "rxp_AllGovernmentsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/rxp/2024", "localname": "AllGovernmentsMember", "presentation": [ "http://xbrl.sec.gov/rxp/role/ByGovernment" ], "lang": { "en-us": { "role": { "label": "All Governments [Member]", "terseLabel": "All Governments" } } }, "auth_ref": [] }, "rxp_AllProjectsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/rxp/2024", "localname": "AllProjectsMember", "presentation": [ "http://xbrl.sec.gov/rxp/role/ByProject" ], "lang": { "en-us": { "role": { "label": "All Projects [Member]", "terseLabel": "All Projects" } } }, "auth_ref": [] }, "dei_AmendmentDescription": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AmendmentDescription", "presentation": [ "http://xbrl.sec.gov/dei/role/document/DocumentInformation" ], "lang": { "en-us": { "role": { "label": "Amendment Description", "terseLabel": "Amendment Description", "documentation": "Description of changes contained within amended document." } } }, "auth_ref": [] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AmendmentFlag", "presentation": [ "http://nutexhealth.com/role/DocumentDocumentAndEntityInformation", "http://xbrl.sec.gov/dei/role/document/DocumentInformation" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "terseLabel": "Amendment", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "rxp_Bonuses": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/rxp/2024", "localname": "Bonuses", "crdr": "debit", "presentation": [ "http://xbrl.sec.gov/rxp/role/ByCategory", "http://xbrl.sec.gov/rxp/role/ByGovernment", "http://xbrl.sec.gov/rxp/role/ByProject" ], "lang": { "en-us": { "role": { "label": "Bonuses", "terseLabel": "Bonuses" } } }, "auth_ref": [] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CityAreaCode", "presentation": [ "http://nutexhealth.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "rxp_Cm": { "xbrltype": "conversionMethodItemType", "nsuri": "http://xbrl.sec.gov/rxp/2024", "localname": "Cm", "presentation": [ "http://xbrl.sec.gov/rxp/role/Detail" ], "lang": { "en-us": { "role": { "label": "Currency Conversion Method", "terseLabel": "Curr. Conv. Method" } } }, "auth_ref": [] }, "rxp_Co": { "xbrltype": "enumerationItemType", "nsuri": "http://xbrl.sec.gov/rxp/2024", "localname": "Co", "presentation": [ "http://xbrl.sec.gov/rxp/role/Detail" ], "lang": { "en-us": { "role": { "label": "Country", "terseLabel": "Country" } } }, "auth_ref": [] }, "rxp_CommunityAndSocial": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/rxp/2024", "localname": "CommunityAndSocial", "crdr": "debit", "presentation": [ "http://xbrl.sec.gov/rxp/role/ByCategory", "http://xbrl.sec.gov/rxp/role/ByGovernment", "http://xbrl.sec.gov/rxp/role/ByProject" ], "lang": { "en-us": { "role": { "label": "Community and Social Responsibility", "terseLabel": "Comm. Social Resp." } } }, "auth_ref": [] }, "rxp_CountryAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/rxp/2024", "localname": "CountryAxis", "presentation": [ "http://xbrl.sec.gov/rxp/role/ByGovernment" ], "lang": { "en-us": { "role": { "label": "Country [Axis]", "terseLabel": "Country:" } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "terseLabel": "Cover", "documentation": "Cover page." } } }, "auth_ref": [] }, "rxp_Dividends": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/rxp/2024", "localname": "Dividends", "crdr": "debit", "presentation": [ "http://xbrl.sec.gov/rxp/role/ByCategory", "http://xbrl.sec.gov/rxp/role/ByGovernment", "http://xbrl.sec.gov/rxp/role/ByProject" ], "lang": { "en-us": { "role": { "label": "Dividends", "terseLabel": "Dividends" } } }, "auth_ref": [] }, "dei_DocumentInformationLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentInformationLineItems", "presentation": [ "http://xbrl.sec.gov/dei/role/document/DocumentInformation" ], "lang": { "en-us": { "role": { "label": "Document Information [Line Items]", "terseLabel": "Document Information:", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "dei_DocumentInformationTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentInformationTable", "presentation": [ "http://xbrl.sec.gov/dei/role/document/DocumentInformation" ], "lang": { "en-us": { "role": { "label": "Document Information [Table]", "terseLabel": "Document Information", "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentPeriodEndDate", "presentation": [ "http://nutexhealth.com/role/DocumentDocumentAndEntityInformation", "http://xbrl.sec.gov/dei/role/document/DocumentInformation" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "terseLabel": "Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentType", "presentation": [ "http://nutexhealth.com/role/DocumentDocumentAndEntityInformation", "http://xbrl.sec.gov/dei/role/document/DocumentInformation" ], "lang": { "en-us": { "role": { "label": "Document Type", "terseLabel": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressAddressLine1", "presentation": [ "http://nutexhealth.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressAddressLine2", "presentation": [ "http://nutexhealth.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Adress Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressCityOrTown", "presentation": [ "http://nutexhealth.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://nutexhealth.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://nutexhealth.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address State Or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCentralIndexKey", "presentation": [ "http://nutexhealth.com/role/DocumentDocumentAndEntityInformation", "http://xbrl.sec.gov/dei/role/document/DocumentInformation" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "terseLabel": "CIK", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r1" ] }, "dei_EntityDomain": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityDomain", "presentation": [ "http://xbrl.sec.gov/rxp/role/ByCategory", "http://xbrl.sec.gov/rxp/role/ByGovernment", "http://xbrl.sec.gov/rxp/role/ByProject", "http://xbrl.sec.gov/rxp/role/Detail" ], "lang": { "en-us": { "role": { "label": "All Entities [Member]", "terseLabel": "All Entities", "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://nutexhealth.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r1" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityFileNumber", "presentation": [ "http://nutexhealth.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://nutexhealth.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityRegistrantName", "presentation": [ "http://nutexhealth.com/role/DocumentDocumentAndEntityInformation", "http://xbrl.sec.gov/dei/role/document/DocumentInformation" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "terseLabel": "Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r1" ] }, "dei_EntityReportingCurrencyISOCode": { "xbrltype": "currencyItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityReportingCurrencyISOCode", "presentation": [ "http://xbrl.sec.gov/dei/role/document/DocumentInformation" ], "lang": { "en-us": { "role": { "label": "Entity Reporting Currency ISO Code", "terseLabel": "Reporting Currency", "documentation": "The three character ISO 4217 code for the currency used for reporting purposes. Example: 'USD'." } } }, "auth_ref": [] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://nutexhealth.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r1" ] }, "rxp_Fees": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/rxp/2024", "localname": "Fees", "crdr": "debit", "presentation": [ "http://xbrl.sec.gov/rxp/role/ByCategory", "http://xbrl.sec.gov/rxp/role/ByGovernment", "http://xbrl.sec.gov/rxp/role/ByProject" ], "lang": { "en-us": { "role": { "label": "Fees", "terseLabel": "Fees" } } }, "auth_ref": [] }, "rxp_GovernmentAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/rxp/2024", "localname": "GovernmentAxis", "presentation": [ "http://xbrl.sec.gov/rxp/role/ByGovernment" ], "lang": { "en-us": { "role": { "label": "Government [Axis]", "terseLabel": "Government:" } } }, "auth_ref": [] }, "rxp_Gv": { "xbrltype": "enumerationItemType", "nsuri": "http://xbrl.sec.gov/rxp/2024", "localname": "Gv", "presentation": [ "http://xbrl.sec.gov/rxp/role/Detail" ], "lang": { "en-us": { "role": { "label": "Government", "terseLabel": "Govt." } } }, "auth_ref": [] }, "rxp_InfrastructureImprovements": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/rxp/2024", "localname": "InfrastructureImprovements", "crdr": "debit", "presentation": [ "http://xbrl.sec.gov/rxp/role/ByCategory", "http://xbrl.sec.gov/rxp/role/ByGovernment", "http://xbrl.sec.gov/rxp/role/ByProject" ], "lang": { "en-us": { "role": { "label": "Infrastructure Improvements", "terseLabel": "Infrastructure" } } }, "auth_ref": [] }, "rxp_K": { "xbrltype": "yesItemType", "nsuri": "http://xbrl.sec.gov/rxp/2024", "localname": "K", "presentation": [ "http://xbrl.sec.gov/rxp/role/Detail" ], "lang": { "en-us": { "role": { "label": "In-kind", "terseLabel": "In-kind" } } }, "auth_ref": [] }, "rxp_Km": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/rxp/2024", "localname": "Km", "presentation": [ "http://xbrl.sec.gov/rxp/role/Detail" ], "lang": { "en-us": { "role": { "label": "In-kind Value Calculation", "terseLabel": "In-kind Calc." } } }, "auth_ref": [] }, "dei_LegalEntityAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "LegalEntityAxis", "presentation": [ "http://xbrl.sec.gov/rxp/role/ByCategory", "http://xbrl.sec.gov/rxp/role/ByGovernment", "http://xbrl.sec.gov/rxp/role/ByProject", "http://xbrl.sec.gov/rxp/role/Detail" ], "lang": { "en-us": { "role": { "label": "Legal Entity [Axis]", "terseLabel": "Legal Entity:", "documentation": "The set of legal entities associated with a report." } } }, "auth_ref": [] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "LocalPhoneNumber", "presentation": [ "http://nutexhealth.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "rxp_M": { "xbrltype": "extractionMethodItemType", "nsuri": "http://xbrl.sec.gov/rxp/2024", "localname": "M", "presentation": [ "http://xbrl.sec.gov/rxp/role/Detail" ], "lang": { "en-us": { "role": { "label": "Extraction Method", "terseLabel": "Ext. Method" } } }, "auth_ref": [] }, "rxp_P": { "xbrltype": "enumerationItemType", "nsuri": "http://xbrl.sec.gov/rxp/2024", "localname": "P", "presentation": [ "http://xbrl.sec.gov/rxp/role/Detail" ], "lang": { "en-us": { "role": { "label": "Payment Type", "terseLabel": "Type" } } }, "auth_ref": [] }, "rxp_PaymentsByCategoryTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/rxp/2024", "localname": "PaymentsByCategoryTable", "lang": { "en-us": { "role": { "label": "Payments by Category [Table]", "terseLabel": "Payments:" } } }, "auth_ref": [] }, "rxp_PaymentsByGovernmentTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/rxp/2024", "localname": "PaymentsByGovernmentTable", "lang": { "en-us": { "role": { "label": "Payments by Government [Table]", "terseLabel": "Payments, by Government:" } } }, "auth_ref": [] }, "rxp_PaymentsByProjectTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/rxp/2024", "localname": "PaymentsByProjectTable", "lang": { "en-us": { "role": { "label": "Payments by Project [Table]", "terseLabel": "Payments, by Project:" } } }, "auth_ref": [] }, "rxp_PaymentsDetailTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/rxp/2024", "localname": "PaymentsDetailTable", "lang": { "en-us": { "role": { "label": "Payments Detail [Table]", "terseLabel": "Payments Detail:" } } }, "auth_ref": [] }, "rxp_PaymentsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/rxp/2024", "localname": "PaymentsLineItems", "presentation": [ "http://xbrl.sec.gov/rxp/role/ByCategory", "http://xbrl.sec.gov/rxp/role/ByGovernment", "http://xbrl.sec.gov/rxp/role/ByProject", "http://xbrl.sec.gov/rxp/role/Detail" ], "lang": { "en-us": { "role": { "label": "Payments [Line Items]", "terseLabel": "Payments:" } } }, "auth_ref": [] }, "rxp_PmtAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/rxp/2024", "localname": "PmtAxis", "presentation": [ "http://xbrl.sec.gov/rxp/role/Detail" ], "lang": { "en-us": { "role": { "label": "Pmt [Axis]", "terseLabel": "#" } } }, "auth_ref": [] }, "rxp_Pr": { "xbrltype": "enumerationItemType", "nsuri": "http://xbrl.sec.gov/rxp/2024", "localname": "Pr", "presentation": [ "http://xbrl.sec.gov/rxp/role/Detail" ], "lang": { "en-us": { "role": { "label": "Project", "terseLabel": "Project" } } }, "auth_ref": [] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://nutexhealth.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r3" ] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "PreCommencementTenderOffer", "presentation": [ "http://nutexhealth.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r5" ] }, "rxp_ProductionEntitlements": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/rxp/2024", "localname": "ProductionEntitlements", "crdr": "debit", "presentation": [ "http://xbrl.sec.gov/rxp/role/ByCategory", "http://xbrl.sec.gov/rxp/role/ByGovernment", "http://xbrl.sec.gov/rxp/role/ByProject" ], "lang": { "en-us": { "role": { "label": "Production Entitlements", "terseLabel": "Prod. Entitlements" } } }, "auth_ref": [] }, "rxp_ProjectAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/rxp/2024", "localname": "ProjectAxis", "presentation": [ "http://xbrl.sec.gov/rxp/role/ByProject" ], "lang": { "en-us": { "role": { "label": "Project [Axis]", "terseLabel": "Project:" } } }, "auth_ref": [] }, "rxp_R": { "xbrltype": "enumerationItemType", "nsuri": "http://xbrl.sec.gov/rxp/2024", "localname": "R", "presentation": [ "http://xbrl.sec.gov/rxp/role/Detail" ], "lang": { "en-us": { "role": { "label": "Resource", "terseLabel": "Resource" } } }, "auth_ref": [] }, "rxp_Royalties": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/rxp/2024", "localname": "Royalties", "crdr": "debit", "presentation": [ "http://xbrl.sec.gov/rxp/role/ByCategory", "http://xbrl.sec.gov/rxp/role/ByGovernment", "http://xbrl.sec.gov/rxp/role/ByProject" ], "lang": { "en-us": { "role": { "label": "Royalties", "terseLabel": "Royalties" } } }, "auth_ref": [] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "Security12bTitle", "presentation": [ "http://nutexhealth.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r0" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "SecurityExchangeName", "presentation": [ "http://nutexhealth.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r2" ] }, "rxp_Sg": { "xbrltype": "enumerationItemType", "nsuri": "http://xbrl.sec.gov/rxp/2024", "localname": "Sg", "presentation": [ "http://xbrl.sec.gov/rxp/role/Detail" ], "lang": { "en-us": { "role": { "label": "Segment", "terseLabel": "Segment" } } }, "auth_ref": [] }, "rxp_Sn": { "xbrltype": "enumerationItemType", "nsuri": "http://xbrl.sec.gov/rxp/2024", "localname": "Sn", "presentation": [ "http://xbrl.sec.gov/rxp/role/Detail" ], "lang": { "en-us": { "role": { "label": "Subnational Jurisdiction", "terseLabel": "Subnat. Juris." } } }, "auth_ref": [] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "SolicitingMaterial", "presentation": [ "http://nutexhealth.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r4" ] }, "rxp_Taxes": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/rxp/2024", "localname": "Taxes", "crdr": "debit", "presentation": [ "http://xbrl.sec.gov/rxp/role/ByCategory", "http://xbrl.sec.gov/rxp/role/ByGovernment", "http://xbrl.sec.gov/rxp/role/ByProject" ], "lang": { "en-us": { "role": { "label": "Taxes", "terseLabel": "Taxes" } } }, "auth_ref": [] }, "rxp_TotalPayments": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/rxp/2024", "localname": "TotalPayments", "crdr": "debit", "presentation": [ "http://xbrl.sec.gov/rxp/role/ByCategory", "http://xbrl.sec.gov/rxp/role/ByGovernment", "http://xbrl.sec.gov/rxp/role/ByProject" ], "lang": { "en-us": { "role": { "label": "Total Payments", "terseLabel": "Total Payments" } } }, "auth_ref": [] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "TradingSymbol", "presentation": [ "http://nutexhealth.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "WrittenCommunications", "presentation": [ "http://nutexhealth.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r6" ] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14a", "Subsection": "12" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" } } } ZIP 18 0001479681-24-000008-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001479681-24-000008-xbrl.zip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end XML 19 nutx-20240808x8k_htm.xml IDEA: XBRL DOCUMENT 0001479681 2024-08-08 2024-08-08 0001479681 false 8-K 2024-08-08 NUTEX HEALTH INC. DE 001-41346 11-3363609 6030 S. Rice Ave Suite C Houston TX 77081 713 660-0557 false false false false Common Stock, $0.001 par value NUTX NASDAQ false